{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:35:48Z","timestamp":1775741748350,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital"},{"name":"Jeff and Judy Buzen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12871-017-0339-x","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T12:41:01Z","timestamp":1490100061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial)"],"prefix":"10.1186","volume":"17","author":[{"given":"Matthew H.","family":"Anstey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Wibrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharusan","family":"Thevathasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigit","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushi","family":"Chhangani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline Yeung","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"DiBiasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Sarge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-0106","authenticated-orcid":false,"given":"Matthias","family":"Eikermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"issue":"1","key":"339_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40360-016-0063-z","volume":"17","author":"C Thongprayoon","year":"2016","unstructured":"Thongprayoon C, Cheungpasitporn W, Harrison AM, Carrera P, Srivali N, Kittamongkolchai W, Erdogan A, Kashani KB. Temporal trends in the utilization of vasopressors in intensive care units: an epidemiologic study. BMC Pharmacol Toxicol. 2016;17(1):19.","journal-title":"BMC Pharmacol Toxicol"},{"key":"339_CR2","unstructured":"Midodrine Information [ https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm225468.htm ]. Accessed 1 Mar 2017."},{"issue":"1","key":"339_CR3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/WNL.51.1.120","volume":"51","author":"RA Wright","year":"1998","unstructured":"Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose\u2013response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120\u20134.","journal-title":"Neurology"},{"issue":"13","key":"339_CR4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","volume":"277","author":"PA Low","year":"1997","unstructured":"Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group. JAMA. 1997;277(13):1046\u201351.","journal-title":"JAMA"},{"issue":"1","key":"339_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","volume":"95","author":"J Jankovic","year":"1993","unstructured":"Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38\u201348.","journal-title":"Am J Med"},{"issue":"10","key":"339_CR6","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/ndt\/gfh420","volume":"19","author":"S Prakash","year":"2004","unstructured":"Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant. 2004;19(10):2553\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"339_CR7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jcrc.2013.05.021","volume":"28","author":"AR Levine","year":"2013","unstructured":"Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, Ryan C, Ball SA, Eikermann M. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013;28(5):756\u201362.","journal-title":"J Crit Care"},{"issue":"4","key":"339_CR8","doi-asserted-by":"crossref","first-page":"224A","DOI":"10.1378\/chest.1990326","volume":"146","author":"JL Cardenas-Garcia","year":"2014","unstructured":"Cardenas-Garcia JL, Withson M, Healy L, Koenig S, Narasimhan M, Mayo P. Safety of oral midodrine as a method of weaning from intravenous vasoactive medication in the medical intensive care unit. Chest. 2014;146(4):224A.","journal-title":"Chest"},{"issue":"6","key":"339_CR9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chest.2016.02.657","volume":"149","author":"MR Whitson","year":"2016","unstructured":"Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH. Feasibility, utility, and safety of midodrine during recovery phase from septic shock. Chest. 2016;149(6):1380\u20133.","journal-title":"Chest"},{"issue":"11","key":"339_CR10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1017\/S0265021502251352","volume":"19","author":"B O'Donnell","year":"2002","unstructured":"O'Donnell B, Synnott A. Midodrine, an alternative to intravenous vasopressor therapy after spinal surgery. Eur J Anaesthesiol. 2002;19(11):841\u20132.","journal-title":"Eur J Anaesthesiol"},{"issue":"1","key":"339_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/107424840501000109","volume":"10","author":"S Sharma","year":"2005","unstructured":"Sharma S, Bhambi B. Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy. J Cardiovasc Pharmacol Ther. 2005;10(1):77\u20139.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"339_CR12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1074248408317709","volume":"13","author":"S Sharma","year":"2008","unstructured":"Sharma S, Lardizabal JA, Bhambi B. Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting. J Cardiovasc Pharmacol Ther. 2008;13(2):94\u20137.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"339_CR13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"339_CR14","unstructured":"FDA Proposes Withdrawal of Low Blood Pressure Drug: Companies failed to provide evidence of clinical benefit of midodrine hydrochloride [ https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm222580.htm ]. Accessed 1 Mar 2017."},{"key":"339_CR15","unstructured":"Midodrine update [ https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm225444.htm ]. Accessed 1 Mar 2017."},{"issue":"19","key":"339_CR16","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1001\/jama.2010.1695","volume":"304","author":"SS Dhruva","year":"2010","unstructured":"Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA. 2010;304(19):2172\u20133.","journal-title":"JAMA"},{"issue":"8","key":"339_CR17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2011.161","volume":"305","author":"NA Holtzman","year":"2011","unstructured":"Holtzman NA, Starfield B. Withdrawing FDA approval of midodrine after marketing. JAMA. 2011;305(8):781\u20132. author reply 782.","journal-title":"JAMA"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-017-0339-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T09:07:57Z","timestamp":1498381677000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-017-0339-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1186\/s12871-017-0339-x","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]},"article-number":"47"}}